Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-71.25%
operating margin TTM
-65.33%
revenue TTM
76.38 Million
revenue per share TTM
0.64$
valuation ratios | |
|---|---|
| pe ratio | -13.91 |
| peg ratio | -0.40 |
| price to book ratio | 12.37 |
| price to sales ratio | 9.72 |
| enterprise value multiple | -17.08 |
| price fair value | 12.37 |
profitability ratios | |
|---|---|
| gross profit margin | 90.27% |
| operating profit margin | -65.33% |
| pretax profit margin | -70.92% |
| net profit margin | -71.25% |
| return on assets | -40.14% |
| return on equity | -77.2% |
| return on capital employed | -47.93% |
liquidity ratio | |
|---|---|
| current ratio | 4.15 |
| quick ratio | 3.97 |
| cash ratio | 0.88 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 277.18 |
| operating cycle | 412.88 |
| days of payables outstanding | 271.35 |
| cash conversion cycle | 141.53 |
| receivables turnover | 2.69 |
| payables turnover | 1.35 |
| inventory turnover | 1.32 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.32 |
| debt equity ratio | 0.70 |
| long term debt to capitalization | 0.40 |
| total debt to capitalization | 0.41 |
| interest coverage | -4.73 |
| cash flow to debt ratio | -1.01 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.97 |
| cash per share | 1.88 |
| operating cash flow per share | -0.93 |
| free cash flow operating cash flow ratio | 1.05 |
| cash flow coverage ratios | -1.01 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -21.81 |
Frequently Asked Questions
When was the last time Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) reported earnings?
Arcutis Biotherapeutics, Inc. (ARQT) published its most recent earnings results on 06-11-2024.
What is Arcutis Biotherapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)'s trailing twelve months ROE is -77.2%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Arcutis Biotherapeutics, Inc. (ARQT) currently has a ROA of -40.14%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ARQT's net profit margin stand at?
ARQT reported a profit margin of -71.25% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ARQT's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.15 in the most recent quarter. The quick ratio stood at 3.97, with a Debt/Eq ratio of 0.70.